Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of recombinant human calcineurin B subunit

A drug delivery technology, bel-7402, is applied in the application field of recombinant human calcineurin B subunit, which can solve the problem of no killing or inhibition of liver cancer cells.

Inactive Publication Date: 2016-03-30
HAIKOU QILI PHARMA
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, there are no relevant reports on the killing or inhibiting effect of rhCNB on liver cancer cells Bel-7402

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant human calcineurin B subunit
  • Application of recombinant human calcineurin B subunit
  • Application of recombinant human calcineurin B subunit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1B

[0038] Example 1 Establishment of BALB / c Nude Mice Bearing Human Hepatoma Cell Bel-7402 Subcutaneously Transplanted Tumor Model

[0039] Human liver cancer cell Bel-7402 was routinely cultured in vitro, digested and centrifuged to make a concentration of about 1×10 7 1 cell / mL cell suspension, 0.2 mL / only was inoculated subcutaneously in the right axilla of the mouse.

Embodiment 2B

[0040] Example 2 Establishment of BALB / c Nude Mice Bearing Human Hepatoma Cell Bel-7402 Orthotopic Transplantation Model

[0041] The well-grown subcutaneous xenografts were taken out and cut into tumor tissue pieces about 2×2×1 mm in size for later use. The animals to be inoculated were gas anesthetized with isoflurane and fed for 12 hours before the operation. After the animals were anesthetized, they were placed in a supine position, and the skin was cut horizontally at 2-5 mm below the xiphoid process layer by layer, with an opening of about 1 cm to expose the liver. Seven days after the operation, detection, grouping and drug administration were performed with a small animal in vivo imaging system.

Embodiment 3

[0042] Embodiment 3 animal grouping

[0043] Take 90 inoculated nude mice and randomly divide them into rhCNB high-dose group for injection, rhCNB middle-dose group for injection, rhCNB low-dose group for injection, rhCNB dose-increasing group for injection and positive control rhCNB injection group according to bioluminescence detection data. Recombinant human interleukin-2 administration group, positive control cisplatin high-dose injection group, positive control cisplatin low-dose injection group, positive control hydroxycamptothecin injection group and vehicle control group Group, 10 in each group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of proteins, in particular to application of recombinant human calcineurin B subunit, and mainly provides application of rhCNB to preparation of a medicine for killing and / or inhibiting a liver cancer cell Bel-7402. After continuous medication for 6 times, medication groups of rhCNB for injection with doses of 10 mg / kg, 20 mg / kg and 40 mg / kg all have a relatively good inhibiting effect on the growth of human liver cancer cell Bel-7402 solid tumors. Subsequent testing results show that the effects of high-dose, middle-dose and increasing-dose medication groups are superior to that of a low-dose medication group, and the treating effect of rhCNB for injection is equivalent to those of recombinant human interleukin-2 for injection and hydroxycamptothecine for injection in a solvent control group. The results of d7 testing after final medication show that the high-dose group has the optimum controlling effect (p is smaller than 0.01) on tumor cell proliferation, which is superior to those of other dose groups and a positive control group, and equivalent to those of a hydroxycamptothecine medication group and the increasing-dose group (p is smaller than 0.05).

Description

technical field [0001] The invention relates to the field of proteins, in particular to the application of recombinant human calcineurin subunit B. Background technique [0002] Calcineurin (CN) is the only known Ca-dependent 2+ / CaM (calmodulin) protein phosphatase, composed of A, B subunits in a 1:1 ratio. The A subunit (CNA) is the catalytic subunit and the B subunit (CNB) is the regulatory subunit. CN plays an important role in the immune activation pathway, which is the key to T cell activation. As a macromolecular enzyme protein, CN is easily inactivated and unstable, while CNB, as the regulatory subunit of the enzyme, can promote the activity of CNA, and has a small relative molecular mass and stable properties. Studies have shown that CNB can stimulate the proliferation of T cells and NK cells, enhance the killing activity of NK cells, enhance the phagocytosis of macrophages and other immune functions, and the recombinant human Calcineurin B subunit (rhCNB) is a g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/46A61P35/00
CPCA61K38/465A61K9/0019C12Y301/03016
Inventor 田树红符健韩克胜黄宗文韩丽芳
Owner HAIKOU QILI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com